Prices delayed by at least 15 minutes | Print


Sanofi SA (0A2V)

SANOFI ADR REP 1 1/2 ORD (CDI)
Change: 0.64 (1.21%)

Open 

$53.14


Previous close 

$52.93


Trade high 

$53.57


Volume 

426


Year high 

$60.0836


Year low 

$46.05


Dividend yield 

3.85%


Market capitalisation 

$129.38 bn


P/E ratio 

18.70


ISIN 

US80105N1054


This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISAand can be used with Dividend reinvestment

Share price

Dividends

PreviousLatest
Record date10/05/202409/05/2025
Ex-dividend date09/05/202409/05/2025
Payment date06/06/202412/06/2025
Amount$2.03736$2.21215

Performance 28/04/2025

1D | 1M | 3M | 1Y | 3Y ann | 5Y ann | 10Y ann


Total return (%)
Sanofi SA+ 0.57
More...

Company profile

Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

Sector 

Healthcare


News

Recent trades

DateTimePriceQuantityValue
29/04/202504:27:1853.6689483.01
29/04/202504:10:0953.57804,285.60
29/04/202503:32:0852.976327462,436.91
29/04/202502:55:2453.05761005,305.76
29/04/202502:54:1953.046925492,599.30

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.